DYN
Dyne TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive pivotal/registrational readouts and a strategic partner would validate Dyne’s delivery platform, supporting a recovery toward prior highs and a re‑rating to the bull target.
Posture
Defensive
Lead driver
Momentum
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Clinical trial failure or negative readouts
Momentum
52
Value
41
Sentiment
0
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $8.00 · Bull $12.00 · Bear $5.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $38.31
Why
Momentum52 · Δ7d +15.6
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
52
34% active weight
Current posture
7d trendImproving
Δ7d
+15.6
Δ21d
+2.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 51.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.08B
Beta
1.31
Shares Out
161.59M
P/E (TTM) · Derived
-5.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.61
Rev YoY
-
EPS YoY
+20.9%
Gross Margin
-
Op Margin
-
Net Debt
-$642.27M
Current Ratio
13.47
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology